Good to see someone here that's interested. I've been involved with the company practically from the day it first became public. I still believe it represents a tremendous opportunity, is severely undervalued, but beyond new partnerships, they really need drugs moving into Pivotal Trials to move the stock to highs not seen in a decade.
The news that BT-062 is moving to Phase III and IMGN is Opting In may be the news that really moves the stock up dramatically. I believe that will occur this year, but I can't say when. There are several trials reporting later this year at ASCO and other conferences, I believe the news will largely be positive.
Gary
News 
Market Data 
Discover 
